Live Breaking News & Updates on Moves In Sympathytuesday|Page 1

Shares of Zogenix, Inc. (NASDAQ: ZGNX) traded higher by 200 percent early Friday morning after the company announced top-line results from a phase 3 clinical trial exploring its drug called ZX008 for the treatment of Dravet syndrome.
Zogenix said that its trial met its primary objective of. Read More.
Don t Miss Any Updates!
News Directly in Your Inbox
Subscribe to: ....

Alan Brochstein , Adam Feuerstein , Gw Pharma Epidiolexmonday , Joseph Sullivan , Gw Pharma Epidiolex , Terms Stoke Therapeutics Inc , Takeda Pharmaceutical Co Ltd , Ovid Therapeutics Inc , Zogenix Inc , Gw Pharmaceuticals , Dravet Syndrome , Pharmaceutical Co Ltd , Weedmaps New , What You Need To Knowtuesday , Stoke Therapeutics , Regulatory Filing For Zogenix Epilepsy Drug , Moves In Sympathytuesday , Late Stage Study Confirms Efficacy , Soars On Positive Phase , Dravet Syndrome Studythursday , Analyst Color , Aras Azadian , Greenwich Bioscience Phase , Dravet Syndrome Treatment Returns , Strong Resultsfriday , ஆலன் ப்ரோச்ஸ்டீன் ,